Condition
Refractory Lupus Nephritis
Total Trials
5
Recruiting
4
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Recruiting4
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06947460Phase 1RecruitingPrimary
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947473Phase 1RecruitingPrimary
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
NCT07403188RecruitingPrimary
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT06676631Phase 1Recruiting
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
NCT06377228Phase 1WithdrawnPrimary
A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)
Showing all 5 trials